The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
Open accessAbstract
Chemoresistance has been a significant problem affecting the efficacy of drugs targeting tumors for decades. MGMT, known as O6-methylguanine-DNA methyltransferase, is a DNA repair enzyme that plays an important role in chemoresistance to alkylating agents. Hence, MGMT is considered a promising target for tumor treatment. Several methods are employed to detect MGMT, each with its own advantages and disadvantages. Some of the detection methods are; immunohistochemistry, methylation-specific PCR (MSP), pyrophosphate sequencing, MGMT activity test, and real-time quantitative PCR. Methylation of MGMT promoter is a key predictor of whether alkylating agents can effectively control glioma cells. The prognostic value of MGMT in glioma is currently being explored. The expression of MGMT gene mainly depends on epigenetic modification - methylation of CpG island of MGMT promoter. CpG island covers a length of 762 bp, with 98 CpG sites located at the 5' end of the gene, ranging from 480 to 1480 nucleotides. The methylation sites and frequencies of CpG islands vary in MGMT-deficient tumor cell lines, xenografts of glioblastoma and in situ glioblastoma. Methylation in some regions of promoter CpG islands is particularly associated with gene expression. The change in the methylation status of the MGMT promoter after chemotherapy, radiotherapy or both is not completely understood, and results from previous studies have been controversial. Several studies have revealed that chemotherapy may enhance MGMT expression in gliomas. This could be through gene induction or selection of high MGMT-expressing cells during chemotherapy. Selective survival of glioma cells with high MGMT expression during alkylating agent therapy may change MGMT status in case of recurrence. Several strategies have been pursued to improve the anti-tumor effects of temozolomide. These include the synthesis of analogues of O6-meG such as O6-benzylguanine (O6-BG) and O6-(4-bromothenyl) guanine (O6-BTG), RNAi, and viral proteins. This review describes the regulation of MGMT expression and its role in chemotherapy, especially in glioma. Targeting MGMT seems to be a promising approach to overcome chemoresistance. Further studies exploring new agents targeting MGMT with better curative effect and less toxicity are advocated. We anticipate that these developments will improve the current poor prognosis of glioma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Pruitt, K. D., Tatusova, T., & Maglott, D. R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl842 · Cited by 4,481
CpG Islands in vertebrate genomes
Gardiner-Garden, M., & Frommer, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90689-9 · Cited by 3,353
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
Pruitt, K. D. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki025 · Cited by 1,660
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P. J., Aigner, L., Brawanski, A., Bogdahn, U., & Beier, C. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4180 · Cited by 1,153
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains
Day, R. S., Ziolkowski, C. H. J., Scudiero, D. A., Meyer, S. A., Lubiniecki, A. S., Girardi, A. J., Galloway, S. M., & Bynum, G. D. (1980) · Nature · doi:10.1038/288724a0 · Cited by 366
Corticosteroids compromise survival in glioblastoma
Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S., Dai, C., Ozawa, T., Chang, M., Chan, T. A., et al. (2016) · Brain · doi:10.1093/brain/aww046 · Cited by 363
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma
Pistollato, F., Abbadi, S., Rampazzo, E., Persano, L., Della Puppa, A., Frasson, C., Sarto, E., Scienza, R., D'avella, D., & Basso, G. (2010) · Stem Cells · doi:10.1002/stem.415 · Cited by 322
Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
Wang, F., Marshall, C. B., & Ikura, M. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1254-4 · Cited by 309
Felsberg, J., Thon, N., Eigenbrod, S., Hentschel, B., Sabel, M. C., Westphal, M., Schackert, G., Kreth, F. W., Pietsch, T., Löffler, M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26083 · Cited by 297
Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma
Beier, D., Röhrl, S., Pillai, D. R., Schwarz, S., Kunz-Schughart, L. A., Leukel, P., Proescholdt, M., Brawanski, A., Bogdahn, U., Trampe-Kieslich, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6878 · Cited by 294
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 255
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Preusser, M., Charles Janzer, R., Felsberg, J., Reifenberger, G., Hamou, M., Diserens, A., Stupp, R., Gorlia, T., Marosi, C., Heinzl, H., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00153.x · Cited by 242
MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Everhard, S., Kaloshi, G., Crinière, E., Benouaich‐Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang‐Xuan, K., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21044 · Cited by 215
Qian, X. C., & Brent, T. P. (1997) · PubMed · Cited by 214
Watts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., & Futscher, B. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5612 · Cited by 214
Costello, J. F., Futscher, B. W., Tano, K., Graunke, D. M., & Pieper, R. O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32544-9 · Cited by 200
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., Kang, C., You, Y., Jiang, C., Song, S. W., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos089 · Cited by 196
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Everhard, S., Tost, J., El Abdalaoui, H., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177
Alonso, M. M., Gomez‐Manzano, C., Bekele, B. N., Yung, W. K. A., & Fueyo-Margareto, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-5312 · Cited by 170
Malley, D. S., Hamoudi, R., Kocialkowski, S., Pearson, D. M., Collins, V. P., & Ichimura, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0803-5 · Cited by 152
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 149
Fritz, G., Tano, K., MITRA, S. P., & Kaina, B. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.9.4660-4668.1991 · Cited by 145
Brandes, A. A., Franceschi, E., Tosoni, A., Bartolini, S., Bacci, A., Agati, R., Ghimenton, C., Turazzi, S., Talacchi, A., Škrap, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop050 · Cited by 143
Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene
Harris, L. C., Potter, P. M., Tano, K., Shiota, S., MITRA, S. P., & Brent, T. P. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.22.6163 · Cited by 139
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldm036 · Cited by 138
Ranson, M., Middleton, M., Bridgewater, J., Lee, S., Dawson, M., Jowle, D., Halbert, G., Waller, S., McGrath, H., Gumbrell, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2198 · Cited by 135
GILBERT, M. R., Wang, M., Aldape, K., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2006 · Cited by 134
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 129
Kato, T., Natsume, A., Toda, H., Iwamizu, H., Sugita, T., Hachisu, R., Watanabe, R., Yuki, K., Motomura, K., Bankiewicz, K. S., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.88 · Cited by 127
Paranjpe, A., Zhang, R., Ali‐Osman, F., Bobustuc, G. C., & Srivenugopal, K. S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt366 · Cited by 121
Kanai, R., Rabkin, S. D., Yip, S. S. F., Sgubin, D., Zaupa, C., Hirose, Y., Louis, D. N., Wakimoto, H., & Martuza, R. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr509 · Cited by 120
Grombacher, T., MITRA, S. P., & Kaina, B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2329 · Cited by 119
Christmann, M., Nagel, G., Horn, S., Krahn, U., Wiewrodt, D., Sommer, C., & Kaina, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25229 · Cited by 117
Costello, J., Futscher, B. W., Kroes, R. A., & Pieper, R. O. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6515 · Cited by 117
Wiewrodt, D., Nagel, G., Dreimüller, N., Hundsberger, T., Perneczky, A., & Kaina, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23219 · Cited by 114
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.
Middleton, M., & Margison, G. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00959-8 · Cited by 114
Uno, M., Oba‐Shinjo, S. M., Camargo, A. A., de Moura, R. P., de Aguiar, P. H. P., Cabrera, H. N., Begnami, M. F. S., Rosemberg, S., Teixeira, M. J., & Marie, S. K. N. (2011) · Clinics · doi:10.1590/s1807-59322011001000013 · Cited by 109
Gene promoter methylation and cancer: An umbrella review
Bouras, E., Karakioulaki, M., Bougioukas, K. I., Aivaliotis, M., Tzimagiorgis, G., & Chourdakis, M. (2019) · Gene · doi:10.1016/j.gene.2019.06.023 · Cited by 100
Papachristodoulou, A., Signorell, R. D., Werner, B., Brambilla, D., Luciani, P., Çavuşoğlu, M., Grandjean, J., Silginer, M., Rudin, M., Martin, E., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.009 · Cited by 99
Melguizo, C., Prados, J. C., González, B., Ortíz, R., Concha, Á., Alvarez, P. J., Madeddu, R., Perazzoli, G., Oliver, J. A., López, R., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-250 · Cited by 95
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Crinière, E., Kaloshi, G., Laigle–Donadey, F., Lejeune, J., Auger, N., Benouaich‐Amiel, A., Everhard, S., Mokhtari, K., Polivka, M., Delattre, J., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9320-0 · Cited by 93
Boldogh, I. R., Ramana, C. V., Chen, Z., Biswas, T., Hazra, T. K., Grösch, S., Grombacher, T., MITRA, S. P., & Kaina, B. (1998) · PubMed · Cited by 92
Pandith, A. A., Qasim, I., Zahoor, W., Shah, P., Bhat, A. R., Sanadhya, D., Shah, Z. A., & Naykoo, N. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25169-2 · Cited by 88
Pieper, R. O., Patel, S. A., Ting, S. A., Futscher, B. W., & Costello, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13916 · Cited by 87
Serial Pyrosequencing for Quantitative DNA Methylation Analysis
Tost, J., abdalaoui, H. E., & Gut, I. G. (2006) · BioTechniques · doi:10.2144/000112190 · Cited by 70
Broniscer, A., Gururangan, S., MacDonald, T. J., Goldman, S., Packer, R. J., Stewart, C. F., Wallace, D., Danks, M. K., Friedman, H. S., Poussaint, T. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1016 · Cited by 68
Phase II Trial of Gliadel plus O 6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme
Quinn, J. A., Jiang, X. “., CARTER, J. H., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2130 · Cited by 68
Switzeny, O. J., Christmann, M., Renovanz, M., Giese, A., Sommer, C., & Kaina, B. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0204-7 · Cited by 67
Bhakat, K. K., & MITRA, S. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005447200 · Cited by 63
Tomicic, M. T., Meise, R., Aasland, D., Berte, N., Kitzinger, R., Krämer, O. H., Kaina, B., & Christmann, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5274 · Cited by 58
Clemons, M. J., Kelly, J., Watson, A. J., Howell, A., McElhinney, R. S., McMurry, T. B. H., & Margison, G. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602833 · Cited by 57
Kaina, B., Mühlhausen, U., Piée‐Staffa, A., Christmann, M., Boy, R. G., Rösch, F., & Schirrmacher, R. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071316 · Cited by 57
Mantwill, K., Naumann, U., Seznec, J., Girbinger, V., Lage, H., Surowiak, P., Beier, D., Mittelbronn, M. G. A., Schlegel, J., & Holm, P. S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-216 · Cited by 53
Aasland, D., Reich, T. R., Tomicic, M. T., Switzeny, O. J., Kaina, B., & Christmann, M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14262 · Cited by 51
Mur, P., de Lope, Á. R., Diaz-Crespo, F. J., Hernández‐Iglesias, T., Ribalta, T., Fiaño, C., García, J. F., REY, J. A., Mollejo, M., & Meléndez, B. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1738-9 · Cited by 48
Watson, A. J., Middleton, M. R., McGown, G., Thorncroft, M. R., Ranson, M., Hersey, P., McArthur, G. A., Davis, I. D., Thomson, D. B., Beith, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605015 · Cited by 48
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT
Nie, E., Jin, X., Wu, W., Yu, T., Zhou, X., Shi, Z., Zhang, J., Liu, N., & You, Y. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2425-9 · Cited by 48
Koch, D., Hundsberger, T., Boor, S., & Kaina, B. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9244-8 · Cited by 46
Overview of DNA methylation in adult diffuse gliomas
Aoki, K., & Natsume, A. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00339-w · Cited by 45
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Quinn, J. A., Jiang, X. “., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-007 · Cited by 42
Turriziani, M., Caporaso, P., Bonmassar, L., Buccisano, F., Amadori, S., Venditti, A., Cantonetti, M., D’Atri, S., & Bonmassar, E. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2005.12.001 · Cited by 39
Inactivation ofO6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors
Reinhard, J., Eichhorn, U., Wießler, M., & Kaina, B. (2001) · International Journal of Cancer · doi:10.1002/ijc.1336 · Cited by 36
Tawbi, H. A.-H., Villaruz, L. C., Tarhini, A. A., Moschos, S. J., Sulecki, M., Viverette, F., Shipe-Spotloe, J. M., Radkowski, R., & Kirkwood, J. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.285 · Cited by 36
Tumor O6-methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib
Watson, A. J., Sabharwal, A., Thorncroft, M. R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1389 · Cited by 34
Happold, C., Stojcheva, N., Silginer, M., Weiss, T., Roth, P., Reifenberger, G., & Weller, M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14326 · Cited by 34
Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas
Jiang, H., Alonso, M. M., Gomez‐Manzano, C., Piao, Y., & Fueyo-Margareto, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.11.1585 · Cited by 31
Costello, J., Futscher, B. W., Kroes, R. A., & Pieper, R. O. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6515-6521.1994 · Cited by 30
Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors
Tomaszowski, K.-H., Schirrmacher, R., & Kaina, B. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00341 · Cited by 28
Tomaszowski, K.-H., Hellmann, N., Ponath, V., Takatsu, H., Shin, H., & Kaina, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-14129-x · Cited by 24
Javanmard, S., Loktionova, N. A., Fang, Q., Pauly, G. T., Pegg, A. E., & Moschel, R. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0705859 · Cited by 22
Schnell, O., Albrecht, V. S., Pfirrmann, D., Eigenbrod, S., Krebs, B., Romagna, A., Siller, S., Giese, A., Tonn, J., & Schichor, C. (2018) · Medical Oncology · doi:10.1007/s12032-018-1162-z · Cited by 2
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Benjaskulluecha, S., Boonmee, A., Pattarakankul, T., Wongprom, B., Klomsing, J., & Palaga, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-05929-x · Cited by 34
Metadata
- Authors
- Yu, W., Zhang, L., Wei, Q., & Shao, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-17
- Volume
- 9
- Pages
- 1547-1547
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2999983497
- Cited by
- 271
- References
- 84
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.